William Blair Weighs in on Penumbra’s Q1 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN) – Stock analysts at William Blair dropped their Q1 2025 EPS estimates for Penumbra in a research note issued on Wednesday, April 2nd. William Blair analyst M. Andrew now forecasts that the company will post earnings of $0.66 per share for the quarter, down from their prior estimate of $0.79. The consensus estimate for Penumbra’s current full-year earnings is $3.67 per share. William Blair also issued estimates for Penumbra’s Q2 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.83 EPS, Q4 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $0.99 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.11 EPS, Q3 2026 earnings at $1.30 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.48 EPS, FY2026 earnings at $4.88 EPS and FY2026 earnings at $4.88 EPS.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million.

PEN has been the topic of several other research reports. Oppenheimer began coverage on shares of Penumbra in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price objective on the stock. Citigroup upped their price target on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. raised their price objective on Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Morgan Stanley upped their target price on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, February 19th. Finally, Piper Sandler reissued an “overweight” rating and set a $330.00 target price (up previously from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $294.47.

Penumbra Trading Down 4.0 %

PEN opened at $262.37 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The company’s 50 day moving average price is $274.48 and its two-hundred day moving average price is $245.61. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of 771.66, a PEG ratio of 2.83 and a beta of 0.51.

Insider Activity

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the sale, the executive vice president now owns 66,539 shares of the company’s stock, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Maggie Yuen sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $286.00, for a total value of $572,000.00. Following the sale, the chief financial officer now owns 15,243 shares of the company’s stock, valued at approximately $4,359,498. This represents a 11.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,236 shares of company stock worth $31,222,390 in the last three months. Company insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. UMB Bank n.a. lifted its position in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new position in shares of Penumbra during the fourth quarter valued at approximately $56,000. Huntington National Bank boosted its position in shares of Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after buying an additional 154 shares during the last quarter. Mather Group LLC. grew its holdings in Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in Penumbra by 893.5% in the 1st quarter. Versant Capital Management Inc now owns 308 shares of the company’s stock valued at $82,000 after buying an additional 277 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.